Name | IDF-11774 |
Description | IDF-11774 is a HIF-1 inhibitor.It reduces hif-1α HRE luciferase activity (IC50 = 3.65 μM). |
Animal Research | When IDF-11774 is orally administered daily for two weeks, significant dose-dependent tumor regression is observed in the mouse model. |
In vitro | IDF-11774 treatment suppressed angiogenesis of cancer cells by reducing the expression of HIF-1 target genes, reduced glucose uptake, thereby sensitizing cells to growth under low glucose conditions, and decreased the extracellular acidification rate (ECAR) and oxygen consumption rate of cancer cells. |
In vivo | Luciferase activity and HIF-1α accumulation are significantly suppressed in the tumors of mice treated with oral administration of IDF-11774, compared to the control. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 60 mg/mL (162.82 mM)
|
Keywords | inhibit | HIF-PH | IDF 11774 | Hypoxia-inducible factors | HIFs | IDF11774 | IDF-11774 | Inhibitor | HIF/HIF Prolyl-Hydroxylase |
Inhibitors Related | Deferoxamine Mesylate | Hydralazine hydrochloride | 1,4-DPCA | Chlorogenic Acid | Glucosamine | Hydroxycitric acid tripotassium hydrate | Glucosamine hydrochloride | Minocycline hydrochloride | Oltipraz | Acriflavine Hydrochloride | Glucosamine sulfate | Cinnamaldehyde |
Related Compound Libraries | Reprogramming Compound Library | Anti-Pancreatic Cancer Compound Library | Bioactive Compound Library | HIF-1 Signaling Pathway Compound Library | Anti-Cancer Metabolism Compound Library | Inhibitor Library | NO PAINS Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library |